Lexeo Therapeutics, Inc. · NASDAQ:LXEO
Lexeo Therapeutics — Technical Presentation (November 2026)
14 slides from Lexeo Therapeutics's technical presentation, Nov 7, 2026
Slide 1: LX2021, an AAV-Based Gene Therapy Improves Cardiomyopathy Phenotypes and Lifespan in DSP Mouse Model
LX2021, AN AAV-BASED GENE THERAPY IMPROVES CARDIOMYOPATHY PHENOTYPES AND LIFESPAN IN A SEVERE DESMOPLAKIN CARDIOMYOPATHY MOUSE MODEL Jing Zhang Ph.D. | Assistant Project Scientist, UCSD Nov. 07, 2026 #ScientificSessions26
Slide 2: Disclosure
DISCLOSURE Dr Farah Sheikh was a cofounder of Stelios Therapeutics Inc (Acquired by LEXEO Therapeutics Inc) and is a cofounder and has an equity interest in Papillon Therapeutics Inc and MyoTherapeutix Inc, as well as is a consultant for LEXEO Therapeutics Inc. This study is funded by LEXEO Therapeu
Slide 3: Desmoplakin (DSP) Cardiomyopathy: A Severe Genetic Disease Without A Targeted Therapy
Desmoplakin (DSP) Cardiomyopathy: A Severe Genetic Disease Without A Targeted Therapy Left Dominant DSP Cardiomyopathy • Severe genetic arrhythmogenic cardiomyopathy, characterized by ventricular arrhythmias and sudden cardiac death • Progressive fibrosis, ventricular dysfunction and heart failure L
Slide 4: Dsp-cKO Mouse Model Shows Dsp Deficiency Leads to Severe Cardiac Remodeling and Death
Cardiac-specific Dsp Knockout (Dsp-cKO) Mouse Model Showed that Dsp Deficiency Is Sufficient to Lead to Severe Cardiac Remodeling and Death Marked by Significant Cardiac Reduction in Connexin43 Dilated RV and LV RV and LV C Extensive Fibrosis B A Enlargement Control DSP-cKO Cardiac Cell-Cell Junctio
Slide 5: Connexin43 Loss Occurs Early Following Dsp Deficiency
Connexin43 Loss Occurs Early Following Dsp Deficiency and Further Reduced In End-Stage Human Arrhythmogenic Cardiomyopathy Hearts DSP flox/flox Early disease • Reduction of connexin43 at cell junctions is thought to be an early consequence of desmosomal deficiency. (Lyon et Connexin43 as a al., 2013
Slide 6: Previous Studies Established AAV-Cx43 As A Therapeutic for DSP Cardiomyopathy
Our Previous Studies Established Connexin43 (AAV-Cx43) As A Therapeutic for DSP Cardiomyopathy Alleviate Reduce Cardiac Restore Cell-Cell Junction Arrhythmia Burden Pathological Remodeling Protein Expression Despite Absence of DSP Prolong Lifespan These data provided proof-of-concept that restoring
Slide 7: LX2021: Translating Cx43 Restoration into a Human Gene Therapy Candidate
LX2021: Translating Cx43 Restoration into a Human Gene Therapy Candidate Postnatal Day 5 (display early arrhythmias) Survival WT 4 weeks 12-13 weeks Vector Copy Number Dsp- Vehicle Surface (Vector cKO 4 weeks ECG 12-13 weeks Exposure) Histology Dsp- AAVrh10.cTNT. cKO hGJA1 (Cx43) 4 weeks 12-13 weeks
Slide 8: LX2021 Attenuates Arrhythmia Burden Early in Dsp-cKO Mice
LX2021 Was Sufficient To Attenuate Arrhythmia Burden Early in DSP Cardiomyopathy (Dsp-cKO) Mice P5 5 weeks old B 3.3 fold 0.29 500 WT N= 5 DSP-cKO+Veh N =14 PVC count in 5 min 400 DSP-cKO+LX2021 N=9 300 200 100 0 8
Slide 9: LX2021 Significantly Improves Survival With Confirmed Cardiac Vector Exposure
LX2021 Significantly Improves Survival With Confirmed Cardiac Vector Exposure In DSP Cardiomyopathy (Dsp-cKO) Mice A C P5 18 weeks old B 7 ✱ WT WT N= 5 VCN/Diploid genome 100 Probability of Survival DSP-cKO+Veh N =14 6 DSP-cKO+Veh DSP-cKO+LX2021 N=10 DSP-cKO+LX2021 * 5 50 2 1 0 0 0 50 100 150 VCN =
Slide 10: LX2021 Reduces Pathological Cardiac Remodeling in Dsp-cKO Mice
LX2021 Reduce Pathological Cardiac Remodeling In DSP Cardiomyopathy (Dsp-cKO) Mice A WT Dsp-cKO+Veh Dsp-cKO+LX2021 H&E Masson’s Trichrome 1mm 0.0034 B 0.0446 LV Chamber area/Total area 0.4 0.5 Fibrosis/muscle area DSP-cKO+Veh N=9 0.4 0.3 DSP-cKO+LX2021 N = 8 0.3 0.2 0.2 0.1 0.1 0.0 0.0 10
Slide 11: LX2021 Restores Junctional Protein Expression Despite Persistent DSP Deficiency
LX2021 Significantly Restores Junctional Protein Expression Despite Persistent DSP Deficiency in DSP Cardiomyopathy (Dsp-cKO) Mice ✱✱✱ ✱✱ Protein expression (Normalized) Protein expression (Normalized) ✱✱✱✱ WT DSP-cKO+Veh DSP-cKO+LX2021 2.5 1.5 WT ✱✱✱ WT 2.0 DSP-cKO+Veh DSP-cKO+Veh Cx43 DSP-cKO+LX20
Slide 12: LX2021 Advances A Mutation-Independent Therapeutic Strategy for DSP Cardiomyopathy
LX2021 Advances A Mutation-Independent Therapeutic Strategy for DSP Cardiomyopathy LX2021 Treatment • Survival • Cardiac Remodeling and Arrhythmia Burden • Cell-Cell Junction Integrity LX2021 demonstrates preclinical efficacy of human GJA1 gene delivery despite persistent DSP deficiency, supporting
Slide 13: Dr. Farah Sheikh's Lab, Alumni and Core Facilities
Dr. Farah Sheikh’s Lab Sheikh Lab Alumni: Core facilities Dr. Erika Gutierrez-Lara Dr. Fabian Zanella Seaweed lab Dr. Afaf Jreije Dr. Yan Liang Dr. Sandra Ratnavadivel Dr. Hank Bradford Dr. Tsui-Min Wang Dr. Jie Wang Ms. Amelia Wignall Dr. Kyohei Fujita Dr. Matthew Ellis Dr. Nithya Selvan Mr. Luca B
Slide 14: Thank you
Thank you #ScientificSessions26
Lexeo Therapeutics — Technical Presentation (November 2026) on 6ix